KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Income (2019 - 2025)

Aurinia Pharmaceuticals' Operating Income history spans 7 years, with the latest figure at $33.2 million for Q4 2025.

  • For Q4 2025, Operating Income rose 2091.55% year-over-year to $33.2 million; the TTM value through Dec 2025 reached $104.9 million, up 2338.4%, while the annual FY2025 figure was $104.9 million, 2338.4% up from the prior year.
  • Operating Income reached $33.2 million in Q4 2025 per AUPH's latest filing, up from $29.7 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $33.2 million in Q4 2025 to a low of -$50.5 million in Q1 2021.
  • Average Operating Income over 5 years is -$14.2 million, with a median of -$16.2 million recorded in 2023.
  • Peak YoY movement for Operating Income: crashed 86.78% in 2021, then soared 2091.55% in 2025.
  • A 5-year view of Operating Income shows it stood at -$32.7 million in 2021, then increased by 14.08% to -$28.1 million in 2022, then decreased by 5.6% to -$29.7 million in 2023, then skyrocketed by 94.38% to -$1.7 million in 2024, then skyrocketed by 2091.55% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Operating Income are $33.2 million (Q4 2025), $29.7 million (Q3 2025), and $20.1 million (Q2 2025).